A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial

By Li Tianhong  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 741-748

Springer Publishing Company

Access to resources Recommend Favorite

Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma

By Burdette-Radoux Susan   Tozer Richard   Lohmann Reinhard   Quirt Ian   Ernst D.   Walsh Wendy   Wainman Nancy   Colevas A.   Eisenhauer Elizabeth  

Investigational New Drugs, Vol. 22, Iss. 3, 2004-08 ,pp. : 315-322

Springer Publishing Company

Access to resources Recommend Favorite

Phase II Study of Perifosine in Previously Untreated Patients with Metastatic Melanoma

By Ernst D   Eisenhauer Elizabeth   Wainman Nancy   Davis Mary   Lohmann Reinhard   Baetz Tara   Belanger Karl   Smylie Michael  

Investigational New Drugs, Vol. 23, Iss. 6, 2005-12 ,pp. : 569-575

Springer Publishing Company

Access to resources Recommend Favorite

A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer

By Kang Yoon-Koo   Muro Kei   Ryu Min-Hee   Yasui Hirofumi   Nishina Tomohiro   Ryoo Baek-Yeol   Kamiya Yukimasa   Akinaga Shiro   Boku Narikazu  

Investigational New Drugs, Vol. 32, Iss. 2, 2014-04 ,pp. : 355-361

Springer Publishing Company

Access to resources Recommend Favorite

Phase II trial of imatinib (Gleevec®) in patients with metastatic renal cell carcinoma

By Vuky Jacqueline   Isacson Christina   Fotoohi Mehran   Cruz Jason   Otero Henry   Picozzi Vincent   Malpass Thomas   Aboulafia David   Jacobs Andrew  

Investigational New Drugs, Vol. 24, Iss. 1, 2006-01 ,pp. : 85-88

Springer Publishing Company

Access to resources Recommend Favorite